Advertisement

The European Journal of Health Economics

, Volume 9, Issue 2, pp 185–191 | Cite as

The impact of generic substitution on price competition in Finland

  • Ville Aalto-SetäläEmail author
Original paper

Abstract

Generic substitution by pharmacists was introduced in April 2003 in Finnish pharmaceutical markets. This article examines the impact of generic substitution on price development. This study examined all of the 2,100 substitutable drugs in Finland. The impact of generic substitution on price competition was significant. The average price of substitutable drugs decreased by more than 10%. However, the price development was uneven; some prices increased whereas others decreased by more than 50%. The most important factors that influenced the price development were the number of competitors, whether the drug was originator or generic and the width of the price band.

Keywords

Generic substitution Pharmaceutical industry Price competition 

JEL codes

D43 L65 

Notes

Acknowledgements

This study was conducted while the author worked as Head of Research for the National Consumer Research Centre (Finland) and Professor of Pharmacoeconomics at the University of Helsinki (Finland). The research did not receive external funding. The author thanks Alan Lyles and Simon Bell for their helpful comments and Paavo Saarinen for data assistance. The author is grateful to the Association of Finnish Pharmacies and the National Agency of Medicines (Finland) for providing the data sets for the research. The author has no conflicts of interest directly relevant to the content of the study.

References

  1. 1.
    Aronsson, T., Bergman, M.A., Rudholm, N.: The impact of generic drug competition on brand name market shares—evidence from micro data. Rev. Ind. Organ. 19(4), 425–435 (2001)CrossRefGoogle Scholar
  2. 2.
    Berndt, E.R.: The U.S. pharmaceutical industry: why major growth in times of cost containment? Health Aff. 20(2), 100–114 (2001)CrossRefGoogle Scholar
  3. 3.
    Boersma, C., Klok, R.M., Bos, J.M., Naunton, M., van den Berg, P.B., de Jong-van den Berg, L.T.W., Postma, M.J.: Drug costs developments after patent expiry of Enalapril, Fluoxetine and Ranitidine: a study conducted for the Netherlands. Appl. Health Econ. Health Policy 4(3), 191–196 (2005)CrossRefGoogle Scholar
  4. 4.
    Congressional Budget Office. How increased competition from generic drugs has affected prices and returns in the pharmaceutical industry. US Government Printing Office, Washington (DC) (1998)Google Scholar
  5. 5.
    Dalen, D.M., Strom, S., Haabeth, T.: Price regulation and generic competition in the pharmaceutical market. Eur. J. Health Econ. 7(3), 208–214 (2006)CrossRefGoogle Scholar
  6. 6.
    de Joncheere, K., Rietveld, A.H., Huttin, C.: Experience with generics. Int. J. Risk Saf. Med. 15, 101–109 (2002)Google Scholar
  7. 7.
    Ellison, S.F., Cockburn, I., Grilliches, Z., Hausman, J.: Characteristics of demand for pharmaceutical products: an examination of four cephalosporins. RAND J. Econ. 28(3), 426–446 (1997)CrossRefGoogle Scholar
  8. 8.
    Ess, S.M., Schneeweiss, S., Szucs, T.D.: European healthcare policies for controlling drug expenditure. Pharmacoeconomics 21(2), 89–103 (2003)CrossRefGoogle Scholar
  9. 9.
    Frank, R.G., Salkever, D.S.: Generic entry and the pricing of pharmaceuticals. J. Econ. Manage. Strategy 6(1), 75–90 (1997)CrossRefGoogle Scholar
  10. 10.
    Garattini, L., Ghislandi, S.: Off-patent drugs in Italy. A short-sighted view?. Eur. J. Health Econ. 7(1), 79–83 (2006)CrossRefGoogle Scholar
  11. 11.
    Lexchin, J.: The effect of generic competition on the price of brand-name drugs. Health Policy 68(1), 47–54 (2004)CrossRefGoogle Scholar
  12. 12.
    Paldan, M., Martikainen, J.: Lääkevaihdon ensimmäinen vuosi tilastoina. In: Riitta, A., Jaana, M. (eds.) Lääkevaihdon ensimmäinen vuosi. Social Insurance Institution, Finland (2005)Google Scholar
  13. 13.
    Poutiainen, T., Aalto-Setälä, V.: Demand for substitutable drugs. University of Helsinki, Mimeo (2006)Google Scholar
  14. 14.
    Simoens, S., De Bruyn, K., Bogaert, M., Laekeman, G.: Pharmaceutical policy regarding generic drugs in Belgium. Pharmacoeconomics 23(8), 755–766 (2005)CrossRefGoogle Scholar
  15. 15.
    Werkö, L.: The rapidly increasing cost of medicines threatens the core of healthcare. Scand. Cardiovasc. J. 38(3), 130–131 (2004)CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  1. 1.Faculty of PharmacyUniversity of HelsinkiHelsinkiFinland

Personalised recommendations